Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL

This study has been completed.
Sponsor:
Information provided by:
Alcon Research
ClinicalTrials.gov Identifier:
NCT00759096
First received: September 23, 2008
Last updated: January 25, 2010
Last verified: January 2010
Results First Received: September 11, 2009  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Visual Acuity
Intervention: Device: RESTOR IOL Model SA60D3

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Eligible patients with bilateral cataract were implanted with ReSTOR lens and followed up for 6-month after the 2nd eye implantation

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Open-label, single arm and nonrandomized

Reporting Groups
  Description
AcrySof ReSTOR IOL Acrysof ReSTOR Intraocular Lens (IOL)

Participant Flow:   Overall Study
    AcrySof ReSTOR IOL  
STARTED     30  
COMPLETED     30  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
AcrySof ReSTOR IOL Acrysof ReSTOR Intraocular Lens (IOL)

Baseline Measures
    AcrySof ReSTOR IOL  
Number of Participants  
[units: participants]
  30  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     3  
>=65 years     27  
Gender  
[units: participants]
 
Female     22  
Male     8  



  Outcome Measures

1.  Primary:   Near Uncorrected Visual Acuity(UCVA   [ Time Frame: 6 months after surgery of 2nd eye ]

2.  Secondary:   Contrast Sensitivity   [ Time Frame: 6 months after sugery of the 2nd eye ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   Yes


  Serious Adverse Events


  Other Adverse Events


  More Information